Verve Therapeutics (VERV) News Today $7.28 -0.55 (-7.02%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$7.44 +0.15 (+2.13%) As of 02/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Verve Therapeutics (NASDAQ:VERV) Trading Down 6.7% - What's Next?Verve Therapeutics (NASDAQ:VERV) Stock Price Down 6.7% - Time to Sell?February 20 at 5:14 PM | marketbeat.comVerve Therapeutics (VERV) Expected to Announce Quarterly Earnings on TuesdayVerve Therapeutics (NASDAQ:VERV) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Up 10.4% - Here's What HappenedVerve Therapeutics (NASDAQ:VERV) Shares Up 10.4% - Here's WhyFebruary 15, 2025 | marketbeat.comNASDAQ:VERV (Verve Therapeutics, Inc.)February 13, 2025 | fool.caVerve Therapeutics (NASDAQ:VERV) Stock Price Down 4.9% - Time to Sell?Verve Therapeutics (NASDAQ:VERV) Stock Price Down 4.9% - What's Next?February 10, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Trading Up 6.7% - Here's What HappenedVerve Therapeutics (NASDAQ:VERV) Shares Up 6.7% - Here's WhyFebruary 5, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Shares Gap Up - What's Next?Verve Therapeutics (NASDAQ:VERV) Shares Gap Up - Should You Buy?February 4, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Trading Down 5.7% - Should You Sell?Verve Therapeutics (NASDAQ:VERV) Stock Price Down 5.7% - What's Next?February 3, 2025 | marketbeat.comKuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law FirmJanuary 31, 2025 | prnewswire.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Nisa Investment Advisors LLCNisa Investment Advisors LLC increased its position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 465.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 42,781 shares of the company's stock after purchasing an additional 35January 30, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Up 5.6% - What's Next?Verve Therapeutics (NASDAQ:VERV) Trading Up 5.6% - Here's What HappenedJanuary 29, 2025 | marketbeat.comVerve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | globenewswire.comVerve Therapeutics (NASDAQ:VERV) Trading Down 8.2% - Here's What HappenedVerve Therapeutics (NASDAQ:VERV) Trading Down 8.2% - Here's What HappenedJanuary 28, 2025 | marketbeat.comCompanies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In GrowthJanuary 27, 2025 | uk.finance.yahoo.comVerve Therapeutics (NASDAQ:VERV) Trading Up 6.1% - Should You Buy?Verve Therapeutics (NASDAQ:VERV) Trading 6.1% Higher - Should You Buy?January 24, 2025 | marketbeat.comCantor Fitzgerald Comments on VERV FY2025 EarningsVerve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Verve Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski aJanuary 23, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Up 6.1% - Here's What HappenedVerve Therapeutics (NASDAQ:VERV) Trading Up 6.1% - Time to Buy?January 22, 2025 | marketbeat.comEquities Analysts Offer Predictions for VERV FY2025 EarningsVerve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Verve Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski forecasts that the company will posJanuary 22, 2025 | marketbeat.comHow Advanced Drug Delivery is Revolutionizing Global Healthcare in 2025January 17, 2025 | baystreet.caVerve Therapeutics (NASDAQ:VERV) Trading 8.6% Higher - Time to Buy?Verve Therapeutics (NASDAQ:VERV) Trading Up 8.6% - Time to Buy?January 16, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Barclays PLCBarclays PLC grew its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 139.8% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 222,919 shares of the company's stock afJanuary 15, 2025 | marketbeat.comVerve Therapeutics announces anticipated 2025 milestonesJanuary 13, 2025 | markets.businessinsider.comVerve Therapeutics sees cash runway into mid-2027January 13, 2025 | markets.businessinsider.comVerve Therapeutics Announces Pipeline Progress and Anticipated 2025 MilestonesJanuary 13, 2025 | finance.yahoo.comVerve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | finance.yahoo.comKuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law FirmJanuary 7, 2025 | markets.businessinsider.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)January 3, 2025 | globenewswire.comVerve Therapeutics (NASDAQ:VERV) Trading 6.2% Higher - What's Next?Verve Therapeutics (NASDAQ:VERV) Stock Price Up 6.2% - Still a Buy?January 3, 2025 | marketbeat.comBarclays PLC Purchases 129,944 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)Barclays PLC grew its position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 139.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 222,919 shares of the company's stock after purchasingDecember 31, 2024 | marketbeat.comWhy Is Verve Therapeutics, Inc. (VERV) Among the Top CRISPR Stocks to Invest In?December 30, 2024 | msn.comVerve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | msn.comVerve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | insidermonkey.comVerve Therapeutics (NASDAQ:VERV) Trading Down 5.9% - Should You Sell?Verve Therapeutics (NASDAQ:VERV) Trading Down 5.9% - Should You Sell?December 27, 2024 | marketbeat.comState Street Corp Boosts Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV)State Street Corp grew its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 27.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,253,217 shares of the company's stock after purchDecember 24, 2024 | marketbeat.comVerve Therapeutics Slides As Insider Purchases Lose Another US$65kDecember 17, 2024 | finance.yahoo.comCharles Schwab Investment Management Inc. Acquires 126,110 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)Charles Schwab Investment Management Inc. lifted its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 28.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 572,December 16, 2024 | marketbeat.comXTX Topco Ltd Makes New $500,000 Investment in Verve Therapeutics, Inc. (NASDAQ:VERV)XTX Topco Ltd acquired a new stake in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 103,348 shares of the company's stock, valued at approximately $500,00December 14, 2024 | marketbeat.comPCSK9 Inhibitors Treatment Market 2034: Clinical Trials, Medication, Pipeline Therapies, EMA, PDMA, FDA Approvals and Companies by DelveInsightDecember 11, 2024 | theglobeandmail.comStifel Nicolaus Sticks to Their Buy Rating for Verve Therapeutics (VERV)December 11, 2024 | markets.businessinsider.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. boosted its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 72.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,559,393 shares of the company's stock afDecember 6, 2024 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Sold by Redmile Group LLCRedmile Group LLC trimmed its stake in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 5.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,383,366 shares of the company's stock after selling 80,040 shares duringDecember 5, 2024 | marketbeat.comVerve Therapeutics: Cutting-Edge Science But Highly Risky StockDecember 4, 2024 | seekingalpha.comPDT Partners LLC Sells 152,061 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)PDT Partners LLC decreased its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 45.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 181,803 shares of the company's stock afterDecember 3, 2024 | marketbeat.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)November 29, 2024 | globenewswire.comBraidwell LP Takes Position in Verve Therapeutics, Inc. (NASDAQ:VERV)Braidwell LP purchased a new position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 623,980 shares of the company's stock, valued at approximately $3,020,000. Braidwell LNovember 29, 2024 | marketbeat.comAlgert Global LLC Increases Stake in Verve Therapeutics, Inc. (NASDAQ:VERV)Algert Global LLC lifted its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 63.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 224,216 shares of the company's stock after buying an additNovember 29, 2024 | marketbeat.comAcuta Capital Partners LLC Takes Position in Verve Therapeutics, Inc. (NASDAQ:VERV)Acuta Capital Partners LLC acquired a new position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 146,100 shares of the company's stock, vNovember 28, 2024 | marketbeat.comGSA Capital Partners LLP Reduces Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)GSA Capital Partners LLP cut its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 82.3% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 36,102 shares of the company's stock after selling 167,575 shares during theNovember 25, 2024 | marketbeat.comVERV FY2024 EPS Estimate Boosted by Cantor FitzgeraldVerve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Verve Therapeutics in a note issued to investors on Monday, November 11th. Cantor Fitzgerald analyst R. Bienkowski now anticipates that the company will post earnings perNovember 14, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for VERV FY2024 Earnings?Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Stock analysts at HC Wainwright cut their FY2024 earnings estimates for Verve Therapeutics in a research note issued to investors on Wednesday, November 6th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings ofNovember 8, 2024 | marketbeat.com Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address VERV Media Mentions By Week VERV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERV News Sentiment▼0.200.60▲Average Medical News Sentiment VERV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERV Articles This Week▼46▲VERV Articles Average Week Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MorphoSys News Today Twist Bioscience News Today Vericel News Today Catalyst Pharmaceuticals News Today MoonLake Immunotherapeutics News Today Merus News Today Beam Therapeutics News Today ImmunityBio News Today Arrowhead Pharmaceuticals News Today HUTCHMED News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERV) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VERV Stock Alerts